Trends in annual price for disease-modifying therapies for multiple sclerosis; 1997 to 2022

**Drug (manufacturer)**

**Self-administered Injections**
- Betaseron (Bayer)
- Avonex (Biogen)
- Rebin (EMD Serono)
- Extavia (Novartis)
- Pliegny (Biogen)
- Kesimpta (Novartis)

**Glatiramer Acetate**
- Copaxone 20 (Teva)
- Copaxone 40 (Teva)
- Glatopa (Sandoz)
- Glat Acet (Mylan)
- Glat Acet 40 (Mylan)

**S1P Receptor Modulators**
- Gilenya (Novartis)
- Mayzent (Novartis)
- Zeposia (Colgene)
- Ponvory (Janssen)

**Fumarates**
- Tecfidera (Biogen)
- Vumerity (Biogen)
- Bafortam (Banner)
- Dimethyl fumarate**

**Other Oral DMTs**
- Aubagio (Genzyme)
- Mavenclad (EMD Serono)

**Infusions**
- Tysabri (Biogen)
- Lemtrada (Genzyme)
- Ocrevus (Genentech)

**Annual Price**
- 1 Year Change*
- 2022

Notes: Annual price estimated from wholesale acquisition costs (First Databank).
Market entry date in parentheses.

**Dimethyl fumarate**: Assumes only inflammatory increases in price (CP). Lerman et al. found that the mean dose of dimethyl fumarate was 12 mg/day (6 vials) for five consecutive days in the first year, 12 mg/day (3 vials) for three days in year 2.

*2021 to 2022 (January): **Lowest price dimethyl fumarate reported.
Updated 2.15.2022 (Data through January 2022)